Ipsen Acquires Memo Therapeutics AG to Add First-in-Class BKPyV Monoclonal Antibody Potravitug

A Phase II/III pivot for a first-in-class monoclonal antibody brings Ipsen into an indication where no targeted approved therapy currently exists. The company announced a definitive share purchase agreement to acquire Memo Therapeutics AG, with the transaction centred entirely on potravitug, a monoclonal antibody directed against the BK polyomavirus VP1 capsid protein, a pathogen responsible for graft-threatening nephropathy in renal transplant recipients.

For CMC leads and contract manufacturing partners, the near-term signal is clear: Ipsen has indicated the pivotal SAFE KIDNEY III trial will initiate later this year, which compresses the timeline for manufacturing scale-up of a clinical-stage mAb carrying both FDA fast-track designation (granted May 2023) and EU orphan drug designation (December 2025). Process validation and comparability protocols will need to be in place ahead of pivotal supply commitments, particularly given the biologics-specific requirements under 21 CFR Part 211 and ICH Q10 quality system expectations for lifecycle management.

The Phase II SAFE KIDNEY II trial, 95 patients across 22 sites in the United States, provides the clinical foundation. Topline data showed 24.4% of potravitug-treated patients achieved undetectable BKPyV-DNAemia by week 38 versus 13.0% in the placebo group. Greater than 2-log10 viral load reductions occurred in 40.3% of treated patients compared with 24.7% on placebo. Biopsy-proven BKPyVAN declined from 51.2% to 31.6% in the treatment arm by week 20, with no corresponding change in the placebo group. No treatment-related serious adverse events were reported.

The full SAFE KIDNEY II dataset was presented at ATC 2026 following an earlier update at the European Renal Association Congress, reinforcing the clinical rationale Ipsen cited when committing to the pivotal programme. BK polyomavirus associated nephropathy carries no currently approved targeted treatment, positioning potravitug as a potential first-mover in a post-transplant infectious complication that can progress to graft loss.

Regulatory affairs teams tracking the orphan drug pathway will note the dual-jurisdiction designation structure: FDA fast-track supports rolling review eligibility in the United States, while EU orphan status provides ten years of market exclusivity upon approval in Europe. Both designations were secured before the acquisition, reducing early regulatory risk for Ipsen as it assumes development stewardship.

The sterility assurance and fill-finish requirements for a parenteral mAb entering pivotal supply will be a key operational checkpoint as Ipsen integrates Memo Therapeutics' programme and aligns manufacturing strategy ahead of SAFE KIDNEY III enrolment.

Source: GlobeNewswire via Ipsen/Memo Therapeutics AG press release, 1 July 2026.